Skip to main content
OpenTrials
Completed

NCT Number: NCT00468819

A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children

In this clinical study a contrast agent for magnetic resonance imaging (MRI), which has already been approved for application in adults, will be investigated in children and adolescents. MRI is a modern and safe examination method without delivering radiation burden using magnetic fields to produce cross-sectional images of the human body. A special computer program then puts these images together and creates a two or three-dimensional image of the inner organs thus facilitating the detection and evaluation of pathological changes. In contrast-enhanced MRI a contrast agent is injected into a peripheral vein before the examination which results in a stronger contrast in the examined area. Therefore, pathological changes can be more easily detected and evaluated compared to non-enhanced MRI. The company Bayer HealthCare Pharmaceuticals has developed a contrast agent for MRI called Gadavist 1.0 which was first approved in 1998 in Switzerland for MRI of brain and spine. Since 2003 Gadavist can also be used in magnetic resonance angiography (MRA) in adults, i.e. in the MRI examination of the blood vessels and since 2006 in MRI of liver and kidney disease. Gadavist was examined in more than 2,900 adults within the framework of clinical studies during development and has been used after its marketing authorization in meanwhile more than 600,000 patients. Yet, clinical studies investigating Gadavist have been only conducted with adults so far. Diseases requiring MRI examinations, however, often occur in children, too. Therefore, many contrast agents are already used on a regular basis in MRI examinations of children, some of these contrast agents being authorized already. Within the framework of this study the pharmacokinetic characteristics of Gadavist in children or adolescents will be investigated, i.e. how the contrast agent is distributed and behaves in the body. In addition, safety and tolerability will be evaluated in order to demonstrate that Gadavist 1.0 is a safe and well tolerated contrast agent also for children and adolescents. Furthermore, the study aims to obtain the dosage recommendation of 0.1 ml per kilogram body weight also for this population group.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Magnetic Resonance Imaging

Age range

2 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Vienna, State of Vienna, Austria

Loading trial locations.

About this study

Please note that the present study is allocated two study phases, i.e. phase I and phase III.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients (male/ female) of specific age groups (2-6 years, 7-11 years, 12-17 years) who are scheduled to undergo Gadolinium (Gd)-enhanced MRI of brain, spine, liver and/or kidneys or Gd-enhanced MRA (single field of view).

Exclusion criteria

  • Clinically unstable patients (e.g. intensive care unit)
  • Renal insufficiency
  • Patients undergoing a relevant change in chemotherapy </= 48 hours prior to and up to 24 hours after the administration of Gadovist.

Treatment and study plan

Gadobutrol (Gadavist, Gadovist, BAY86-4875)

Drug

In an open-label design, all patients will receive a total dose of 0.1 mmol/kg BW Gadovist 1.01 Days Injection

Primary outcomes

  1. Plasma Clearance Estimates of Gadobutrol by Age Group

    Time frame: From injection of Gadobutrol up to 8 hours after injection.

    Total body clearance of Gadobutrol in plasma in L/h after intravenous injection.

  2. Body Weight-corrected Plasma Clearance Estimates of Gadobutrol by Age Group

    Time frame: From injection up to 8 hours after Gadobutrol injection

    Total body clearance of Gadobutrol in plasma corrected for body weight (L/h/kg) after intravenous injection.

  3. Volume Distribution at Steady State (Vss) Estimates of Gadobutrol by Age Group

    Time frame: From injection up to 8 hours after Gadobutrol injection

    Apparent volume of distribution at steady state expressed in L after intravenous injection.

  4. Body Weight-corrected Volume Distribution at Steady State (Vss) Estimates of Gadobutrol by Age Group

    Time frame: From injection to 8 hours after Gadobutrol injection

    Apparent volume of distribution at steady state corrected for body weight (L/h/kg) after intravenous injection.

  5. Area Under the Drug Concentration-time Curve of Gadobutrol by Age Group

    Time frame: From injection to 8 hours after Gadobutrol injection

    Area under the concentration versus time curve from zero to infinity after intravenous injection expressed in µmol*h/L.

  6. Terminal Elimination Half Life Estimates of Gadobutrol by Age Group

    Time frame: From injection to 8 hours after Gadobutrol injection

    Terminal elimination half-life of Gadobutrol from plasma expressed in h and derived from the terminal slope of the concentration versus time curve.

  7. Mean Residence Time (MRT) Estimates of Gadobutrol by Age Group

    Time frame: From injection to 8 hours after Gadobutrol injection

    Mean residence time of Gadobutrol in plasma expressed in h.

Secondary outcomes

  1. Urinary Excretion of Gadolinium as Percent of Administered Dose

    Time frame: up to 6 hours after Gadobutrol injection

    Amount of gadolinium* excreted into urine during the collection interval 0 - 6 h post dose expressed as % of administered dose. *A metallic rare-earth element, used as a contrast medium for magnetic resonance imaging.

  2. Number of Participants With Basic Technical Adequacy of Magnetic Resonance (MR) Images for Diagnosis by Age Group

    Time frame: Up to 1 hour after Gadobutrol injection

    In the participants the technical adequacy (evaluability) of MR images was assessed on the following 4-point scale (1=not adequate [compromised quality], 2=partially adequate [evaluation possible], 3=adequate despite artifacts, 4=adequate with excellent quality).

  3. Number of Participants With Overall Contrast Quality of Post Contrast Images by Age Group

    Time frame: up to 1 hour after Gadobutrol injection

    In the participants qualitative overall contrast quality of post contrast images was assessed on the following 6-point scale (none, poor, moderate, good, excellent, not assessable).

  4. Pre-Contrast Lesions by Location and by Age Group

    Time frame: up to 1 hour after Gadobutrol injection

    Number of lesions on pre-contrast images by organ location and age group.

  5. Post-Contrast Lesions by Location and by Age Group

    Time frame: up to 1 hour after Gadobutrol injection

    Number of lesions on post-contrast images by organ location and age group.

  6. Pre-Contrast Delineation of Lesion/Vessel Border by Age Group

    Time frame: up to 1 hour after Gadobutrol injection

    In the participants pre-contrast delineation of each lesion/vessel border was assessed on the following 5-point scale (no, moderate, good, excellent, not assessable).

  7. Post-Contrast Delineation of Lesion/Vessel Border by Age Group

    Time frame: up to 1 hour after Gadobutrol injection

    In the participants post-contrast delineation of each lesion/vessel border was assessed on the following 5-point scale (no, moderate, good, excellent, not assessable).

  8. Pre-Contrast Lesion Characterization by Age Group

    Time frame: up to 1 hour after Gadobutrol injection

    In the participants the internal morphology and structure of each pre-contrast lesion was assessed on the following 4-point scale (1=poor, 2=moderate, 3=good, 4=not applicable).

  9. Post-Contrast Lesion Characterization by Age Group

    Time frame: up to 1 hour after Gadobutrol injection

    In the participants the internal morphology and structure of each post-contrast lesion was assessed on the following 4-point scale (1=poor, 2=moderate, 3=good, 4=not applicable).

  10. Degree of Contrast Enhancement in Lesion/Vessel by Age Group (Given Are Total Numbers of Lesions)

    Time frame: up to 1 hour after Gadobutrol injection

    In the participants the degree of contrast enhancement in each lesion/vessel was assessed on the following 5-point scale (1=no, 2=moderate, 3=good, 4=excellent, 5=not applicable).

  11. Number of Participants With Change in Diagnostic Confidence by Age Group

    Time frame: up to 1 hour after Gadobutrol injection

    In the participants the change in diagnostic confidence (additional diagnostic gain by the post-contrast scan) was assessed on the following 3-point scale (1=unchanged, 2=improved, 3=worsened).

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

Open-label Multi-center Study of Magnetic Resonance Imaging (MRI) With 0.1 mmol/kg Body Weight (BW) Gadavist (1.0 M) to Assess Pharmacokinetics, Safety and Tolerability in Children.

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
May 3, 2007
Registry last updated
Jul 22, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.